Copyright © 2008 Noriko Sato et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. C. Donaldson, N. Tarrier, and A. Burns, “The impact of the symptoms of dementia on caregivers,” British Journal of Psychiatry, vol. 170, no. 1, pp. 62–68, 1997. View at Publisher · View at Google Scholar
2. I. V. Kurochkin and S. Goto, “Alzheimer's $\beta$-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme,” FEBS Letters, vol. 345, no. 1, pp. 33–37, 1994. View at Publisher · View at Google Scholar
3. W. Q. Qiu, D. M. Walsh, Z. Ye, et al., “Insulin-degrading enzyme regulates extracellular levels of amyloid $\beta$-protein by degradation,” The Journal of Biological Chemistry, vol. 273, no. 49, pp. 32730–32738, 1998. View at Publisher · View at Google Scholar
4. K. Vekrellis, Z. Ye, W. Q. Qiu, et al., “Neurons regulate extracellular levels of amyloid $\beta$-protein via proteolysis by insulin-degrading enzyme,” The Journal of Neuroscience, vol. 20, no. 5, pp. 1657–1665, 2000.
5. W. Farris, S. Mansourian, Y. Chang, et al., “Insulin-degrading enzyme regulates the levels of insulin, amyloid $\beta$-protein, and the $\beta$-amyloid precursor protein intracellular domain in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 4162–4167, 2003. View at Publisher · View at Google Scholar · View at PubMed
6. H. Akiyama, K. Yokono, K. Shii, et al., “Natural regulatory mechanisms of insulin degradation by insulin degrading enzyme,” Biochemical and Biophysical Research Communications, vol. 170, no. 3, pp. 1325–1330, 1990. View at Publisher · View at Google Scholar
7. W.-L. Kuo, A. G. Montag, and M. R. Rosner, “Insulin-degrading enzyme is differentially expressed and developmentally regulated in various rat tissues,” Endocrinology, vol. 132, no. 2, pp. 604–611, 1993. View at Publisher · View at Google Scholar
8. F. Authier, B. I. Posner, and J. J. M. Bergeron, “Insulin-degrading enzyme,” Clinical and Investigative Medicine, vol. 19, no. 3, pp. 149–160, 1996.
9. C. J. Groves, S. Wiltshire, D. Smedley, et al., “Association and haplotype analysis of the insulin-degrading enzyme (IDE) gene, a strong positional and biological candidate for type 2 diabetes susceptibility,” Diabetes, vol. 52, no. 5, pp. 1300–1305, 2003. View at Publisher · View at Google Scholar
10. S. Karamohamed, S. Demissie, J. Volcjak, et al., “Polymorphisms in the insulin-degrading enzyme gene are associated with type 2 diabetes in men from the NHLBI Framingham Heart Study,” Diabetes, vol. 52, no. 6, pp. 1562–1567, 2003. View at Publisher · View at Google Scholar
11. G. J. Biessels, S. Staekenborg, E. Brunner, C. Brayne, and P. Scheltens, “Risk of dementia in diabetes mellitus: a systematic review,” Lancet Neurology, vol. 5, no. 1, pp. 64–74, 2006. View at Publisher · View at Google Scholar · View at PubMed
12. D. G. Cook, J. B. Leverenz, P. J. McMillan, et al., “Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-$\epsilon$4 allele,” The American Journal of Pathology, vol. 162, no. 1, pp. 313–319, 2003.
13. L. Bertram, D. Blacker, K. Mullin, et al., “Evidence for genetic linkage Alzheimer's disease to chromosome 10q,” Science, vol. 290, no. 5500, pp. 2302–2303, 2000. View at Publisher · View at Google Scholar · View at PubMed
14. N. Ertekin-Taner, N. Graff-Radford, L. H. Younkin, et al., “Linkage of plasma A$\beta$42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees,” Science, vol. 290, no. 5500, pp. 2303–2304, 2000. View at Publisher · View at Google Scholar · View at PubMed
15. A. Myers, P. Holmans, H. Marshall, et al., “Susceptibility locus for Alzheimer's disease on chromosome 10,” Science, vol. 290, no. 5500, pp. 2304–2305, 2000. View at Publisher · View at Google Scholar · View at PubMed
16. S. D. Edland, F. Wavrant-De Vriesé, D. Compton, et al., “Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer's disease: evidence of effect modification by apolipoprotein E (APOE),” Neuroscience Letters, vol. 345, no. 1, pp. 21–24, 2003. View at Publisher · View at Google Scholar
17. L. Bian, J. D. Yang, T. W. Guo, et al., “Insulin-degrading enzyme and Alzheimer disease: a genetic association study in the Han Chinese,” Neurology, vol. 63, no. 2, pp. 241–245, 2004.
18. P. Nowotny, A. L. Hinrichs, S. Smemo, et al., “Association studies between risk for late-onset Alzheimer's disease and variants in insulin degrading enzyme,” American Journal of Medical Genetics Part B, vol. 136B, no. 1, pp. 62–68, 2005. View at Publisher · View at Google Scholar · View at PubMed
19. J. C. Mueller, M. Riemenschneider, A. Schoepfer-Wendels, et al., “Weak independent association signals between IDE polymorphisms, Alzheimer's disease and cognitive measures,” Neurobiology of Aging, vol. 28, no. 5, pp. 727–734, 2007. View at Publisher · View at Google Scholar · View at PubMed
20. R. Abraham, A. Myers, F. Wavrant-DeVrieze, et al., “Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease,” Human Genetics, vol. 109, no. 6, pp. 646–652, 2001. View at Publisher · View at Google Scholar · View at PubMed
21. M. Boussaha, D. Hannequin, P. Verpillat, A. Brice, T. Frebourg, and D. Campion, “Polymorphisms of insulin degrading enzyme gene are not associated with Alzheimer's disease,” Neuroscience Letters, vol. 329, no. 1, pp. 121–123, 2002. View at Publisher · View at Google Scholar
22. S. D. Edland, “Insulin-degrading enzyme, apolipoprotein E, and Alzheimer's disease,” Journal of Molecular Neuroscience, vol. 23, no. 3, pp. 213–217, 2004. View at Publisher · View at Google Scholar · View at PubMed
23. A. Sakai, H. Ujike, K. Nakata, et al., “No association between the insulin degrading enzyme gene and Alzheimer's disease in a Japanese population,” American Journal of Medical Genetics Part B, vol. 125B, no. 1, pp. 87–91, 2004. View at Publisher · View at Google Scholar · View at PubMed
24. E. Cellini, S. Bagnoli, A. Tedde, B. Nacmias, S. Piacentini, and S. Sorbi, “Insulin degrading enzyme and alpha-3 catenin polymorphisms in Italian patients with Alzheimer disease,” Alzheimer Disease and Associated Disorders, vol. 19, no. 4, pp. 246–247, 2005. View at Publisher · View at Google Scholar
25. A. Ozturk, S. T. DeKosky, and M. I. Kamboh, “Lack of association of 5 SNPs in the vicinity of the insulin-degrading enzyme (IDE) gene with late-onset Alzheimer's disease,” Neuroscience Letters, vol. 406, no. 3, pp. 265–269, 2006. View at Publisher · View at Google Scholar · View at PubMed
26. L. Marlowe, R. Peila, K. S. Benke, et al., “Insulin-degrading enzyme haplotypes affect insulin levels but not dementia risk,” Neurodegenerative Diseases, vol. 3, no. 6, pp. 320–326, 2007. View at Publisher · View at Google Scholar · View at PubMed
27. B. Reisberg, “Dementia: a systematic approach to identifying reversible causes,” Geriatrics, vol. 41, no. 4, pp. 30–46, 1986.
28. I. Gélinas, L. Gauthier, M. McIntyre, and S. Gauthier, “Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia,” American Journal of Occupational Therapy, vol. 53, no. 5, pp. 471–481, 1999.
29. P. R. Wenham, W. H. Price, and G. Blundell, “Apolipoprotein E genotyping by one-stage PCR,” The Lancet, vol. 337, no. 8750, pp. 1158–1159, 1991. View at Publisher · View at Google Scholar
30. B. Reisberg, E. Franssen, S. G. Sclan, A. Kluger, and S. H. Ferris, “Stage specific incidence of potentially remediable behavioral symptoms in aging and alzheimer disease. A study of 120 patients using the BEHAVE-AD,” Bulletin of Clinical Neurosciences, vol. 54, pp. 95–112, 1989.
31. N. Scarmeas, J. Brandt, M. Albert, et al., “Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease,” Neurology, vol. 58, no. 8, pp. 1182–1188, 2002.
32. B. Reisberg, J. Borenstein, S. P. Salob, S. H. Ferris, E. Franssen, and A. Georgotas, “Behavioral symptoms in Alzheimer's disease: phenomenology and treatment,” The Journal of Clinical Psychiatry, vol. 48, pp. 9–15, 1987.
33. W. E. Haley and K. M. Pardo, “Relationship of severity of dementia to caregiving stressors,” Psychology and Aging, vol. 4, no. 4, pp. 389–392, 1989. View at Publisher · View at Google Scholar
34. W. Y. W. Mok, L. W. Chu, C. P. Chung, N. Y. Chan, and S. L. Hui, “The relationship between non-cognitive symptoms and functional impairment in Alzheimer's disease,” International Journal of Geriatric Psychiatry, vol. 19, no. 11, pp. 1040–1046, 2004. View at Publisher · View at Google Scholar · View at PubMed
35. M. M. Bassiony and C. G. Lyketsos, “Delusions and hallucinations in Alzheimer's disease: review of the brain decade,” Psychosomatics, vol. 44, no. 5, pp. 388–401, 2003. View at Publisher · View at Google Scholar
36. N. Hirono, E. Mori, K. Ishii, et al., “Frontal lobe hypometabolism and depression in Alzheimer's disease,” Neurology, vol. 50, no. 2, pp. 380–383, 1998.
37. D. E. Kuhl, E. J. Metter, W. H. Riege, and R. A. Hawkins, “The effect of normal aging on patterns of local cerebral glucose utilization,” Annals of Neurology, vol. 15, pp. 133–137, 1984. View at Publisher · View at Google Scholar
38. P. J. Goodnick, J. H. Henry, and V. M. V. Buki, “Treatment of depression in patients with diabetes mellitus,” The Journal of Clinical Psychiatry, vol. 56, no. 4, pp. 128–136, 1995.
39. P. J. Goodnick, “Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy,” Annals of Clinical Psychiatry, vol. 13, no. 1, pp. 31–41, 2001. View at Publisher · View at Google Scholar
40. E. Holsboer-Trachsler, U. Hemmeter, U. von Bardeleben, et al., “Neuroendocrine factors in neurodegenerative and cognitive disorder,” International Academy for Biomedical and Drug Research, vol. 7, pp. 180–186, 1994.